Aptose Biosciences Inc. Issues Press Release on February 18, 2025

Aptose Biosciences Inc. (NASDAQ: APTO) recently announced the release of a press statement on February 18, 2025. The company’s latest communication is in accordance with Item 7.01 of the Form 8-K filing, disclosing the distribution of a press release furnished as Exhibit 99.1.

As per the regulations outlined in General Instruction B.2 of Form 8-K, the information contained in the press release attached as Exhibit 99.1 is not considered to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934. Furthermore, this data is not integrated by reference in any submissions under the Securities Act of 1933 or the Exchange Act, barring specific reference in such filings.

Additionally, under Item 9.01 of the Form 8-K, Aptose Biosciences Inc. includes the following exhibit:
– Exhibit 99.1: Press Release dated February 18, 2025
– Exhibit 104: Cover Page Interactive Data File (embedded within the Inline XBRL document)

The report was signed by William G. Rice, Ph.D., the President and Chief Executive Officer of Aptose Biosciences Inc., on behalf of the company on February 18, 2025. The press release serves as an important means of communicating recent developments and updates to stakeholders and the investing public.

This disclosure by Aptose Biosciences Inc. marks a step in ensuring transparency and regulatory compliance in its reporting practices to the shareholders and the investment community.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aptose Biosciences’s 8K filing here.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.